Zilretta
Zilretta Now Available for Osteoarthritis Knee Pain
December 01, 2017Flexion Therapeutics announced the availability of Zilretta (triamcinolone acetonide extended-release injectable suspension) indicated for the management of pain associated with osteoarthritis (OA) of the knee.
FDA Approves Zilretta NDA for Knee Osteoarthritis
February 16, 2017The Food and Drug Administration has accepted for review the New Drug Application for Zilretta for the treatment of patients with osteoarthritis of the knee.
Clinical Pain Advisor Articles
- Cannabis May Be Effective for Migraine Treatment
- Medicinal Cannabis May Not Have Opioid-Sparing Effects in Chronic Noncancer Pain
- Replacing Sleep, Sedentary Behavior With Physical Activity Beneficial in Knee Osteoarthritis
- Galcanezumab May Result in Functional Improvements in Migraine
- Pregabalin and Celecoxib Reduced Need for Morphine After Lumbar Spine Surgery
- Ketamine: Mechanisms of Action, Uses in Pain Medicine, and Side Effects
- Cannabis May Be Effective for Migraine Treatment
- Medicinal Cannabis May Not Have Opioid-Sparing Effects in Chronic Noncancer Pain
- Integrating Psychological Interventions Into Chronic Pain Management
- Leveraging the Placebo Effect to Reduce Opioid Requirements
- Investigational Treatment Shows Promise in Chronic Low Back Pain
- Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Pain Severity May Partly Mediate the Association Between Depression and Physical Performance in Knee OA
- Rates of Concurrent Opioid, Sedative-Hypnotic Prescription Fills in Veterans
